There is mounting evidence that the neuropeptide oxytocin is a possible candidate for the treatment of drug addiction. Oxytocin was shown to reduce methamphetamine selfadministration, conditioned place-preference, hyperactivity and reinstatement in rodents, highlighting its potential for the management of methamphetamine addiction. Thus, we hypothesised that the central endogenous oxytocinergic system is dysregulated following chronic methamphetamine administration. We tested this hypothesis by examining the effect of chronic methamphetamine administration on oxytocin receptor density in mice brains with the use of quantitative receptor autoradiographic binding. Saline (4 mg/kg/day, i.p.) or methamphetamine (1 mg/kg/day, i.p.) was administered daily for 10 days to male, CD1 mice.
Chronic methamphetamine treatment induces oxytocin receptor up-regulation in the amygdala and hypothalamus via an adenosine A 2A receptor-independent mechanism

Introduction
Methamphetamine (MAP) is a widely abused drug and its use has become of public health concern in many parts of the world. The relatively easy clandestine manufacture and consequently low street cost of MAP means that its use has reached near-epidemic proportions in the United States (see Gonzales et al. , 2010) and multiple cases of epidemic MAP use in Japan have also been reported (see Wada, 2011) . MAP is a highly addictive psychostimulant drug (Woolverton et al. , 1984) that acutely stimulates dopamine release and blocks its re-uptake from the synaptic cleft in the striatum (Krasnova and Cadet, 2009 ), thus inducing euphoric and psychostimulant effects. Chronic use of MAP causes neurotoxic effects and has been shown to induce emotional impairment, including social avoidance and isolation, aggressiveness, depression, anxiety and can also induce psychotic behaviour in humans (Grant et al. , 2012 , McKetin et al. , 2011 ) and animal models (Clemens et al. , 2007 . Currently, pharmacotherapy for addiction to psychostimulant drugs including MAP is limited (Ciccarone, 2011) .
Although several mechanisms have been suggested, the molecular mechanism underpinning the addictive properties of chronic methamphetamine use and its behavioural and emotional consequences remain unclear. Accumulating evidence showing a strong interaction between neuronal markers of social behaviour and those of stress and mood regulation (Dabrowska et al. , 2011 , Debiec, 2005 , Di Simplicio et al. , 2009 , Heinrichs and Gaab, 2007 , Windle et al. , 2004 ) and of drug reward/withdrawal (Liu et al. , 2011 , suggest that the "social" neuropeptide oxytocin (OT) and its receptor (OTR) may be implicated in the modulation of at least some of these methamphetamine-induced effects. OT is primarily synthesized by the magnocellular neurons of the supraoptic (SON) and paraventricular (PVN) 5 nuclei of the hypothalamus projecting to the posterior pituitary gland where it is stored in vesicles and it is released into the bloodstream to exert its peripheral effects (Fig. 1 ).
Oxytocinergic neurons also project from the PVN and innervate brain regions associated with drug-seeking behaviour, stress, mood, fear and emotionality such as the nucleus accumbens, amygdala, septum and the bed nucleus of stria terminalis, where OTRs are located (Gimpl and Fahrenholz, 2001) (Fig. 1) . OT promotes social and sexual bonding and social memory (Keverne and Curley, 2004) and has a marked anxiolytic, anti-aggressive and antidepressant effect in humans when administered as an intranasal spray (Baumgartner et al. , 2008 , Di Simplicio et al., 2009 , Kirsch et al. , 2005 , or in animal models when administered centrally or peripherally (Dabrowska et al., 2011 , Windle et al., 2004 . This has triggered a growing interest in the involvement of OT in psychiatric conditions characterised by symptoms associated with increased anxiety and social withdrawal, such as autism and schizophrenia (Carter, 2007, Heinrichs and Gaab, 2007) .
There is emerging evidence supporting the involvement of OT in the effects of a number of drugs of abuse (Broadbear et al. , 2011 , McGregor and Bowen, 2012 , McGregor et al. , 2008 , Sarnyai, 2011 . With respect to MAP, an inhibitory effect of OT has been demonstrated on MAP-induced hyperlocomotion and conditioned place preference (CPP) (Qi et al. , 2008 , Qi et al. , 2009 ) and on dopamine release in the Acb (Qi et al., 2008) demonstrating a key role for OT in the modulation of behavioural effects of MAP, possibly via a dopaminergicdependent mechanism. Moreover, central (i.c.v) OT administration abolished stress-induced reinstatement of MAP seeking in mice (Qi et al., 2009 ) while peripheral OT administration reduced MAP self-administration and MAP-induced reinstatement in rats (Carson et al. , 2010a ) supporting the oxytocinergic system as a novel pharmacotherapeutic target for MAP 6 relapse prevention. Interestingly, in rats, OT was also recently shown to reduce MAP-induced Fos activation in neurons of the basal ganglia such as the subthalamic nucleus (STh) and the Acb core (AcbC) (Carson et al. , 2010b) , providing further mechanistic evidence behind OTs beneficial effect on attenuating at least some of MAPs effects. Additionally, peripheral administration or microinjections of OT into the STh and Acb core attenuated the formation of methamphetamine-induced CPP (Baracz et al. , 2012 (Ponzio et al. , 2006) . Although yet unknown, it is likely that A 2A receptors may facilitate the excitation of other oxytocinergic neurons (e.g. PVN projections to the reward centers of the brain). Similarly to the effect of OT, activation of A 2A receptors has a prominent role in modulating MAP behavioural effects including attenuation of MAPinduced hyperactivity (Shimazoe et al. , 2000) and stimulus discrimination (Munzar et al. , 2002) , at least partly by inhibiting MAP-induced elevation in dopamine output in the striatum (Golembiowska and Zylewska, 1998, Yoshimatsu et al. , 2001 (Ferre et al. , 2007 , Ferre et al. , 2008 . As OTR and D 2 receptors have recently been
shown to co-localise and facilitate allosteric functional interactions in the nucleus accumbens (McKetin et al., 2011) , it is tempting to hypothesise that OTR (endogenous and exogenous) may also interact with A 2A in the striatum and this interaction might be involved in the modulatory effect of OT on MAP-induced behavioural effects.
The outcomes of these studies have led us to hypothesise that the central endogenous oxytocinergic system may be dysregulated following chronic methamphetamine use. We 
Methods and Materials
Animals
All animal care and experimental procedures complied with protocols approved by the UK Home Office, Animals (Scientific Procedures) Act, 1986. All studies are reported in accordance with the ARRIVE guidelines (McGrath et al. , 2010) , and were designed to 8 minimise suffering and to reduce the number of animals used. 8-12 weeks old, male CD-1 mice were used in all experiments (total number: 24). The animals were individually housed in a temperature-controlled environment, under a 12 h light/dark cycle (lights on: 7.00 am).
Food and water were available ad libitum. Wild type and adenosine A 2A receptor knockout (KO) mice, originally generated by Ledent et al., (1997) were obtained from the breeding colony at the University of Surrey, as previously detailed (Bailey et al. , 2004a , Bailey et al. , 2002a . Briefly, mutant mice were obtained from heterozygote breeding pairs, which originated from the individual crossing of a number of heterozygote males from the existing colony, each with a WT female of the CD-1 strain, purchased from an external supplier (Charles River, UK). All mice were genotyped at weaning using a polymerase chain reaction (PCR) based method. Tail tip samples were collected at 3 weeks of age, and DNA was extracted using the DNeasy tissue kit, according to the manufacturer's instructions (QIAGEN, Germany).
Drug treatment
Mice were randomly divided into four groups; chronic saline-treated WT and KO and chronic MAP-treated WT and KO animals. Chronic MAP-treated animals were injected intraperitoneally (i.p.),once per day (11:00am), for 10 days with MAP (1mg/kg) (SigmaAldrich, Poole, UK) in accordance with studies carried out by Liang et al., (2006) , with minor modifications. The chronic saline-treated group were administered with saline (4ml/kg body weight, i.p.), , once per per day (11:00) for 10 days.
Oxytocin receptor autoradiography
Animals were killed via cervical dislocation 3 h following the last treatment injection (saline or MAP) on Day 10 of the steady-dose MAP administration paradigm. Sections for all treatment groups were processed in parallel and apposed to the same film at the same time.
Confirmation of genotype with autoradiographic binding
To confirm the genotype of the animals used in the present studies, brain sections from the aforementioned treated WT and KO mice were processed for A 2A receptor binding according to Bailey et al., (2004b) , (2002b), (2003). Briefly, sections were pre-incubated for 30 min in 170 mM Tris-HCl buffer, containing 1 mM EDTA (pH 7.4, room temperature). Sections were then incubated for 2 h at room temperature, in 170 mM Tris-HCl buffer, containing 10 nM [ 3 H]CGS21680 (PerkinElmer; specific activity 30 Ci/mmol), 10 nM MgCl 2 , and 2 U/ml adenosine deaminase (pH 7.4). Incubations were terminated by 3 x 5 min washes into ice cold 50 mM Tris buffer (pH 7.4), followed by a rapid rinse in ice cold distilled water.
Radioligand bound sections were apposed to film for a period of 3 weeks and developed as previously described above.
Statistical analysis
Three-way ANOVA for the factors treatment, genotype and brain region were used to compare receptor binding levels in saline-and MAP-treated, WT and adenosine A 2A receptor KO animals. Moreover, two-way ANOVA was performed in each individual brain region for factors 'treatment" and 'genotype'. Where ANOVA yielded significant main effects, post hoc Bonferroni analysis was used to determine differences in radioligand binding between treatment groups.
Statistical significance was set at  level of <0.05. All data were analysed using the Statistica V10 software (Statsoft Inc., France), and are presented as mean ± SEM of 5-6 animals/group. High levels of OTR binding (1.17-1.46fmol/mg) were observed within the olfactory nuclei, moderate levels (0.33-0.85 fmol/mg) in the piriform cortex, septum, amygdala and hypothalamus, and low levels (0.03-0.24fmol/mg) in the cingulate cortex, thalamus, Acb, olfactory tubercle, caudate-putamen in all treatment groups (Fig. 3 
Results
Discussion
This is the first study to demonstrate profound region-specific alterations of the OTR system in the brain following chronic MAP administration, which may be involved in the modulation showed high levels of binding in the olfactory nuclei, septum, amygdala and endopiriform and lower binding in the striatum, thalamus and hippocampus of mice. This distribution of OTR is in sharp contrast to the monogamus prairie vole (Lim et al. , 2004) which shows very high levels of OTR binding in striatal regions including the Acb, the caudate putamen and the olfactory tubercle clearly indicating a striking species difference with respect to OTR localization and density. It is generally accepted that these differences may underline species differences in the ability to form pair bonds (Aragona et al. , 2003 , Wang et al. , 1997 .
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Although dysregulations of the endogenous oxytocin system have been reported following acute or repeated alcohol (Kovacs et al. , 1998) , cocaine (Sarnyai, 1998 , Sarnyai et al. , 1992 , GHB (van Nieuwenhuijzen et al. , 2010) , 3,4-methylenedioxymethamphetamine (MDMA) (Thompson et al. , 2007) and morphine (Kovacs et al. , 1987) Nonetheless, the MAP induced upregulation observed in our study was profound (50-80 %) and was replicated in genetically modified A 2A receptor KO mice.
The significance of this MAP induced upregulation of OTRs is yet to be determined.
However, given the ability of OT to modulate MAP induced hyperactivity (Carson et al., 2010a , Qi et al., 2008 and to attenuate MAP induced CPP (Qi et al., 2009 ) and stress-and priming induced reinstatement of MAP self-administration (Carson et al., 2010a) or CPP (Qi et al., 2009) , it is highly likely that this oxytocinergic dysfunction may be underlining some behavioural consequences of chronic MAP use. Indeed, it has been suggested that based on the ability of OT to supress Fos activity in brain regions associated with motivation and reward such as subthalamic nucleus (STh) and the Acb (Carson et al. , 2010c) , and the ability of OT to reduce MAP induced dopamine activity in Acb (Qi et al., 2008) , OT may be involved in the modulation of the incentive motivational properties of MAP. Based on these observations, alterations of OTR would be been expected in the STh and the Acb following chronic MAP treatment. The reason why these alterations were not observed in these regions may be due to the relatively low expression of OTR in these regions in the CD1 mouse used in the present study (see Fig. 3 , Table 1 ). This does not, however, preclude the possibility that profound changes in OT release occur in these brain regions following chronic MAP administration, which may indeed lead to long-lasting morphological, functional and behavioural changes.
Although alterations of OTR binding were not observed in brain regions traditionally associated with drug dependence, it is important to highlight the possibility of OTR dysregulation taking place in the amygdala in the present study, to influence dopaminergic neurotransmission in the Acb and thus motivation. A clear connection between the Acb and the amygdala has been proposed to control limbic function and motivation. For instance, it has been suggested that the central amygdala affects tonic dopaminergic tone in the ventral tegmental area, thereby regulating dopaminergic tone in the Acb and modulating the incentive value of environmental stimuli (Phillips et al. , 2003) . As a result the profound upregulation of OTR system following chronic MAP administration in the amygdala may affect dopamine levels in the Acb in order to modulate its addictive-related behavioural effects.
The amygdala is a limbic structure which is involved in a number of facets of emotional analysis (Phelps and LeDoux, 2005) and is a key component of social cognitive circuitry in both animals and humans (Rosenfeld et al. , 2011) . There is considerable evidence demonstrating abnormalities in the amygdala following chronic MAP use (Kim et al. , 2011 , London et al. , 2004 which is likely to be at least partly responsible for the development of anxiety, stress, depression (Dawe et al. , 2009 , Goeldner et al. , 2011 , Morley et al. , 2001 , Thompson et al. , 2004 ) and social cognitive deficits (Dawe et al., 2009 , Volkow et al. , 2011 . Given that OT is known to stimulate oxytocinergic neurons in the amygdala (Carson et al., 2010c) and that the amygdala is partly responsible for the prosocial, antidepressant and anxiolytic properties of OT (Baumgartner et al., 2008 , Debiec, 2005 , Domes et al. , 2007 , Febo et al. , 2005 , Febo et al. , 2009 , it would be intriguing to speculate that the upregulation of OTRs in this regions, following chronic MAP administration, may be involved in the modulation of the behavioural consequences of chronic MAP use including depression, anxiety and social deficits. Interestingly, Thompson et al., (2007) strongly implicated the oxytocinergic system of the central medial amygdala in the prosocial effect of the drug MDMA ("ecstasy").
MAP induced upregulation of OTR observed in the present study is likely to be the result of an endogenous central oxytocinergic deficiency which may represent a compensatory homeostatic mechanism to modulate the anxiety, aggressiveness, depression and social deficit and drug seeking motivation evident in MAP dependent individuals (Grant et al., 2012 , McKetin et al., 2011 and in animal models (Clemens et al., 2007 .
Thus, this OTR upregulation may play a protective role in modulating MAP dependence and the consequences of chronic MAP use, which is in line with the efficacy of OT in decreasing MAP self-administration (Carson et al., 2010a) .
Interestingly, chronic MAP also induced an upregulation of OTR in the hypothalalamus, another brain region associated with stress regulation. Given that OT is known to stimulate oxytocinergic neurons in the hypothalamus (Carson et al., 2010c) and that the hypothalamus is partly responsible for the antidepressant and anxiolytic properties of OT (Baumgartner et al., 2008 , Dabrowska et al., 2011 , Di Simplicio et al., 2009 , Kirsch et al., 2005 , Windle et al., 2004 , it would be intriguing to speculate, as in the case of the amygdala, that the upregulation of OTRs in this regions, following chronic MAP administration, may be involved in the modulation of the behavioural consequences of chronic MAP use including depression and anxiety. Further studies are needed to test the validity of this speculation.
Based on the evidence suggesting an involvement of central adenosine A 2A receptors on the endogenous oxytocinergic function in the brain (Ponzio et al., 2006) , we hypothesised that the neuroadaptations of the OTR system following chronic MAP administration may be mediated by an A 2A receptor dependent mechanism. However, as in WT mice, the profound upregulation of OTR following chronic MAP administration was also observed in the hypothalamus and amygdala of MAP-treated A 2A KO mice clearly demonstrating a lack of A 2A involvement in this region-specific upregulation. The reason that we did not observe any modulation of this MAP-induced upregulation in A 2A KO mice might be due to the low expression of A 2A in these brain regions. Although, there is some evidence of A 2A expression in the amygdala (Hume et al. , 1996 , Mak et al. , 2012 and hypothalamus (Kokoshka et al. , 1998 , Volkow et al. , 2009 It is important to point out here that, despite its significant contribution towards understanding the mechanisms underlyining the effects of drugs of abuse, full developmental 18 KO mouse technology does not come without limitations (see review by Yoo et al., (2012) ).
One of the problems arising from studies in KO mice is the emergence of compensatory adaptations of various systems in the mouse triggered by the gene deletion. For instance, an upregulation of opioid receptors has been observed in preproenkephalin and preprodynorphin KO mice (Clarke et al. , 2003) . In the case of A 2A KO, we showed no compensatory changes in D 2 R, MOPr, DOPr, KOPr, 42 and 7 nAChR binding (Bailey et al., 2004a , Bailey et al., 2002a , Campbell et al., 2009 . No change in OTR was also observed in saline-treated A 2A
KO vs WT in the present study. As a result, we can conclude that it is unlikely that the 
